Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in
cutaneous drug reactions
immune- related adverse events
immunotherapy
osimertinib
targeted therapy
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
04
2021
accepted:
13
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in
Identifiants
pubmed: 34179028
doi: 10.3389/fmed.2021.570921
pmc: PMC8220808
doi:
Types de publication
Case Reports
Langues
eng
Pagination
570921Informations de copyright
Copyright © 2021 Ferro, Filoni, Pavan, Pasello, Guarneri, Conte, Alaibac and Bonanno.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Curr Opin Rheumatol. 2018 Sep;30(5):490-497
pubmed: 29870500
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Clin Dermatol. 2011 Nov-Dec;29(6):587-601
pubmed: 22014981
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Melanoma Res. 2019 Apr;29(2):212-215
pubmed: 30489484
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):391-404
pubmed: 24238695
Clin Exp Dermatol. 2009 Oct;34(7):e328-9
pubmed: 19456774
Jpn J Clin Oncol. 2012 Jun;42(6):528-33
pubmed: 22457323
J Thorac Oncol. 2017 Feb;12(2):403-407
pubmed: 27765535
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Ann Rheum Dis. 2019 Jul;78(7):e67
pubmed: 29858173
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Nat Rev Cancer. 2006 Oct;6(10):803-12
pubmed: 16990857
J Thorac Oncol. 2017 Jul;12(7):1109-1121
pubmed: 28461257
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Melanoma Res. 2019 Jun;29(3):338-341
pubmed: 30762712
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Arch Dermatol. 2009 Mar;145(3):340-1
pubmed: 19289781
Br J Dermatol. 2014 Dec;171(6):1559-61
pubmed: 24909204
Ann Oncol. 2015 Sep;26(9):1883-1889
pubmed: 26105600
Arch Dermatol. 1979 Dec;115(12):1409-15
pubmed: 533284
JAMA Dermatol. 2013 Sep;149(9):1071-5
pubmed: 23842655
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
J Cutan Med Surg. 2018 May/Jun;22(3):341-343
pubmed: 29307217
Asia Pac J Clin Oncol. 2018 Feb;14(1):23-31
pubmed: 28464435
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Eur J Dermatol. 2017 Feb 1;27(1):28-33
pubmed: 27799135
Skin Appendage Disord. 2015 Mar;1(1):31-7
pubmed: 27171241
Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9
pubmed: 29462253